Carlos Bosques, Ph.D.

With over 32 million people living with food allergies in the United States alone and only one FDA approved drug, we must innovate to find a solution to this problem. Decoding the cellular and molecular communications between the immune and nervous systems is paramount to effectively intervene with the pathophysiological pathways at the core of food allergies. FASI investigators are paving the way to develop a new and unique level of understanding of these mechanisms. I am honored to have the opportunity to work with this innovative and passionate team in decoding these complex systems and, more importantly, to embark on the translation of these groundbreaking discoveries into alternatives to more effectively diagnose and treat food allergies. Working with the best scientists in our own unconventional approach, I believe we are uniquely positioned to create new alternatives to improve the quality of life for millions of people living with food allergies across the world.

Dr. Carlos Bosques is Chief Executive Officer of the Food Allergy Science Initiative (FASI).

A seasoned biotech executive, innovator, and scientific strategist, Dr. Bosques has dedicated over 20 years to the development of biomedical technology platforms and novel therapeutics. As a passionate drug developer, he is proficient in identifying therapeutic opportunities and developing them from discovery to the clinical stage.

At FASI, Dr. Bosques leads national efforts to transform food allergy care through breakthrough scientific discovery. He is responsible for leveraging the interface of Immunology, Neuroscience, Gastroenterology, and Microbiology to discover and develop therapeutic alternatives to treat food allergies.

Dr. Bosques has advanced multiple first-in-class immunotherapies from early discovery through clinical development, including programs that have secured multi-million dollar partnerships and billion-dollar acquisitions, such as the Johnson & Johnson acquisition of Momenta Pharmaceuticals. With over 70 patents and peer-reviewed publications, he has a proven track record in platform development, IP strategy, and team leadership—scaling R&D organizations across diverse areas including therapeutics, medical devices, and green biomaterials. Dr. Bosques earned his Ph.D. in Biological Chemistry from MIT.